Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

N/AActive Not RecruitingNCT03485378

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's39 enrolled

Overview

This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.

For patients with ILD and concurrent early-stage lung cancer who are not candidates for surgery, data showing high rates of toxicity have led to a difficult clinical dilemma, since there are few alternate treatment options. The option of delivering no treatment whatsoever, which avoids any risk of treatment-related toxicity, is associated with a high risk of death due to the lung cancer itself. Stereotactic ablative radiotherapy (SABR) is a newer radiotherapy approach which uses modern radiotherapy planning and targeting technologies to precisely deliver larger, ablative doses of radiotherapy. SABR has been associated with high rates of local control. A major advantage of SABR is that in general, the toxicity profile is very favorable, even in patients with substantial co-morbid conditions. It is possible that currently-used doses and fractionations of SABR, when given with strict planning criteria to minimize the risk of lung toxicity, have only a modest risk of treatment-related toxicity and represent the best possible approach. This study will examine SABR versus a historical control of untreated stage I non-small cell lung cancer with Overall survival (OS) as the endpoint. OS was selected as it objectively reflects the potential benefits of treatment (i.e. extended survival), the harms of treatment (grade 5 toxicity), and the natural history of the ILD disease process itself.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non Small Cell Lung Cancer Interstitial Lung Disease

Interventions

Stereotactic Ablative RadiotherapyRADIATION

Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stage T1-2, N0, M0 (AJCC Staging, 8th Edition - i.e. tumor size ≤ 5 cm) prior to registration. * Not a candidate for surgical resection, determined by any of the following: * Consultation with a thoracic surgeon * Discussion at Multidisciplinary Team (MDT) rounds with a surgeon present * Patient refusal of surgery * Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer (NSCLC) is not required, but strongly recommended. * If the risk of biopsy is unacceptable, pathologic confirmation is not required providing there is growth over time on Computed Tomography (CT) imaging and/or Fluorodeoxyglucose (FDG) avidity that is strongly suggestive of a primary NSCLC. * Eastern Cooperative Oncology Group (ECOG) performance status 0-3; * Age ≥ 18; * Life expectancy \> 6 months * Fibrotic interstitial lung disease of any subtype, as diagnosed by a respirologist/pulmonologist. Exclusion Criteria: * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (e.g., carcinomas in situ of the breast, oral cavity, or cervix are permissible); previous lung cancer, if the patient is disease-free for a minimum of 2 years is permitted. * Prior thoracic radiotherapy * Plans for the patient to receive other local therapy while on this study, except at disease progression; * Plans for the patient to receive systemic therapy (including standard chemotherapy or biologic targeted agents), while on this study, except at disease progression. Patients are allowed to receive anti-fibrotic agents used in the treatment of IPF or non-IPF fibrotic ILD (e.g. nintedanib, pirfenidone), or steroids, if those are part of their current ILD treatment regimen. Other immunosuppressive drugs such as mycophenolate, azathioprine, cyclophosphamide, and rituximab must be stopped for 2 weeks prior and 2 weeks after treatment. * Active pregnancy * Concurrent administration of any drugs with known radiosensitive effects (e.g. Methotrexate).

Locations (6)

Alberta Health Services, Cross Cancer Institude

Edmonton, Alberta, Canada

London Regional Cancer Program of the Lawson Health Research Institute

London, Ontario, Canada

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

UHN Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Overall Survival

Time from enrollment to death from any cause

Time frame: 4 years

Secondary Outcomes

Toxicity as measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Time frame: 8 years

Progression-Free Survival

Time frame: 8 years

Local Control as determined via radiographic evidence

Time frame: 8 years

Cough Severity as reported by the participant via 10 cm analogue Cough Severity Scale

Cough severity will be reported by participants via a scale, where a score of 100 is no cough and a score of 0 is the worst cough ever.

Time frame: 8 years

Rates of Acute-Exacerbation of Idiopathic Pulmonary Fibrosis (IPF)

Time frame: 8 years

Rates of Acute-Exacerbation of ILD

Time frame: 8 years

Quality of Life measured by the Functional Assessment of Cancer Therapy - Lung questionnaire

The Functional Assessment of Cancer Therapy - Lung (FACT-L ) is a standardized questionnaire used to measure quality of life. The questionnaire consists of 5 scales measuring 37 items in total. Categories of the 5 scales are: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns related to symptoms, cognitive function, and regret of smoking. The score for each item in the scale ranges from 0 to 4, where 0 is not at all and 4 is very much. The scores from each scale are added up, and can be combined to provide a total score.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.